Genetic Modification of Natural Killer Cells for Leukemia Therapies

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Genetic Modification of Natural Killer Cells for Leukemia Therapies

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 6(2): 101-108.

Author(s): Chihaya Imai, Harumi Kakuda, Hiroyuki Fujisaki, Shotaro Iwamoto and Dario Campana.

Affiliation: Department of Oncology, St.Jude Children's Research Hospital, 332 North Lauderdale, Memphis TN 38105-2794, USA.


Natural killer (NK) cells have the capacity to recognize and kill a wide range of cancer cells. However, many cancer cells are resistant to NK cell cytotoxicity, mainly because they express molecules which inhibit NK cell activation. Previous studies have shown that enforced expression of chimeric receptors composed of single-chain variable domain of murine antibodies and human signaling molecules can redirect the specificity of T lymphocytes. The success of this approach depends on the identification of a suitable target molecule on cancer cells and on the ability of the receptor to deliver appropriate activation signals. We developed a method to express chimeric receptors in NK cells. Considerable NK cell expansion was obtained by co-culturing peripheral blood cells with the leukemia cell line K562 modified to express membrane bound-interleukin 15 and the ligand for the costimulatory molecule 4-1BB. Expanded NK cells were then transduced with anti-CD19 receptors which deliver activation signals through CD3ζ and 4-1BB. NK cells expressing these receptors became highly cytotoxic against NK-resistant CD19+ leukemic cells. We here review the methodologies for expanding and redirecting the specificity of NK cells, explain the rationale for NK-cell therapies of leukemia and lymphoma, describe potential targets for genetically-modified NK cells, and discuss future clinical applications of NK cell expansion and genetic modification in cancer therapy.


graft-versus-host disease, killer immunoglobulin-like receptors, immunoreceptor tyrosine-based activation motifs, leukemic cells, B-cell malignancies.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 6
Issue Number: 2
First Page: 101
Last Page: 108
Page Count: 8
DOI: 10.2174/187152307780598108
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science